Breaking News
Celltrion has received U.S. Food and Drug Administration approval for its autoimmune disease treatment drug Steqeyma, a biosimilar of Johnson & Johnson’s Stelara (ustekinumab).
The U.S. Food and Drug Administration (FDA) has granted fast track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1-based immune checkpoint inhibitors.
FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis with Ocaliva who did not have cirrhosis of the liver.
BioTrending
- By Lee Warren
The accomplishments of AI in the healthcare sector are impressive, but as AI continues to improve patient care and enhance provider skills, addressing its challenges will be critical.
- By Keith Berman, MPH, MBA
Affecting more than 100,000 American children and adults, sickle cell disease is an inherited hemoglobinopathy that results when a single-nucleotide mutation in the ß-globin gene yields an abnormal “sickle” hemoglobin (HbS). Now, these patients may be eligible for a one-time gene therapy that offers the potential of a durable functional cure by eliminating severe VOCs and associated hospitalizations.
- By Diane L.M. Cook
For patients with genetic disease, recent evolution of and FDA approval for gene therapies are transforming care and turning an ambitious dream into a life-changing reality. But getting affordable treatments to patients safely and efficiently remains a challenge.
- By Amy Scanlin, MS
The future of healthcare is being driven by digital transformations and emerging technology that provide preventive, personalized and predictive medicine.
BSTQ Podcast: Marketplace News & Insights
Understanding the Insurance Reimbursement Process in Specialty Pharmacy
Special guest expert Leslie Vaughan, Chief Operating Officer of Nufactor, discusses the insurance reimbursement process in specialty pharmacy and how to make it easier for patients.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
